Alentis is a biotech company developing breakthrough treatments for fibrotic diseases.
Alentis discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (esp. hepatocellular carcinoma, HCC).
Alentis Therapeutics was founded in 2019 by Thomas Baumert. The company is based in Basel, Basel-Stadt, Switzerland.
Alentis' unique therapeutic approach focuses on the inhibition of Claudin-1 outside the tight junction and its downstream signalling acting on cell fate and plasticity.
Alentis' lead candidates are monoclonal antibodies that are highly selective for Claudin-1, a novel, previously unexploited target with a unique mechanism of action that plays a key role in the pathology of liver fibrosis and fibrosis-driven hepatobiliary cancers.
Alentis also has early discovery programs exploring the potential of Claudin-1 inhibition in the treatment of fibrosis of other tissues including the kidney and lung. These represent very large and expanding markets with high unmet need.
Alentis is backed by Morningside Venture Investments, Jeito Capital, BioMed Partners, BB Pureos Bioventures, Bpifrance, and others. The company raised CHF60M in Series B round on Jun 15, 2021. This brings Alentis' total funding to CHF72.5M to date.